Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

FOCIS 2015: TET Protein Regulation May Provide Insights for Cancer Treatment

Catherine Kolonko  |  Issue: September 2015  |  September 15, 2015

Laguna Design/sciencesource.com

Image Credit: Laguna Design/sciencesource.com

A presentation given during FOCIS 2015, the 15th annual meeting of the Federation of Clinical Immunity Societies in June 2015 in San Diego, focused on advances in stem cell research related to treatment of cancer and the function that particular enzymes play in disease.

Anjana Rao, PhD, professor at the La Jolla Institute for Allergy and Immunology in San Diego, discussed her research on epigenetics—the process by which genetic information is modified without changing the underlying DNA sequence—and how it influences the function of the immune system by turning genes on and off.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The research undertaken by Dr. Rao has led to seminal, molecular-level discoveries and insights of the immune system, which helps keep the body healthy and plays a key role in cancer and other diseases, Mark Anderson, MD, PhD, of the University of California, San Francisco, told the audience in his introductory remarks.

DNA Methylation

Dr. Rao focused her presentation on the family of TET (ten-eleven translocations) proteins and their role in promoting DNA cytosine demethylation. The proteins regulate gene expression through oxidation of 5-methylcytosine (5mC) and are named after the rare ten-eleven translocation observed in cases of acute myeloid and lymphocytic leukemia.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

There are three TET proteins in humans, mice and other mammals that have been the subject of research as it relates to embryonic stem cells and the development and treatment of cancer. The TET enzymes interact with DNA and help maintain potency in stem cells.

Dr. Rao began her lecture with a discussion of DNA methylation at the 5 position of cytosine. Known as the fifth base in the DNA genome, 5mC is an epigenetic mark created by DNA methyltransferases that plays an essential role in genome regulation and biological development and disease.

TET proteins sequentially oxidize this methyl group by converting 5mC into 5-hydroxymethylcytosine (5-hmC). When the methyl group is added to DNA through the methylation process—a vital part of biological growth and development—it acts as a chemical switch to turn genes on and off.

“What the TET enzymes and other enzymes of this class, known as dioxygenases, are doing is [using] oxygen and 2-oxoglutarate as substrates,” Dr. Rao said. “Therefore, TET enzymes can link metabolism and oxygen sufficiency to epigenetic changes in the genome.”

Scientists have studied how aberrant DNA methylation is able to shut off genes that would normally suppress cancerous tumors, effectively keeping disease at bay. Disruptions in the DNA methylation cycle, including loss of function of TET proteins, have been linked to tumor onset and progression.

TET Function

Dr. Rao

Dr. Rao

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:Cancerpatient careResearchTET proteinTreatmenttrial

Related Articles

    Cellular Therapy of Autoimmune Disease

    November 1, 2008

    Is a novel treatment breakthrough on the horizon?

    2015 ACR/ARHP Annual Meeting: Genetic Links Emerge in Osteoarthritis

    March 15, 2016

    SAN FRANCISCO—As researchers have delved into the genetics behind osteoarthritis (OA), genes that appear to be players in the disease have emerged, but there have also been curveballs thrown, with expectations not always matching up to the genetic realities, an expert said at the 2015 ACR/ARHP Annual Meeting. The genetic risk of acquiring OA is…

    The Latest on Epigenetics in Immune-Mediated Disease

    March 19, 2019

    CHICAGO—Because the epigenome has been implicated in a variety of rheumatic conditions, a Basic Research Conference was convened on Epigenetics in Immune-Mediated Disease in conjunction with the 2018 ACR/ARHP Annual Meeting. Melanie Ehrlich, PhD, professor of human genetics and genomics at Tulane University School of Medicine, New Orleans, opened the conference. She has a long…

    Study Uncovers Tet2’s Role in Resolving Inflammation

    January 11, 2016

    When investigating the role of epigenetic modifiers in inflammatory response, researchers found that Tet2 acts at the chromatin level to help resolve inflammation in both dendritic cells and macrophage, repressing the transcription of IL-6…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences